



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



# Minutes

**Regular Board Meeting**

Wednesday, August 20, 2025  
Louisiana Board of Pharmacy  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809

## **Table of Contents**

<b><u>Agenda Item No.</u></b>	<b><u>Description</u></b>	<b><u>Page No.</u></b>
1.	Call to Order	03
2.	Invocation & Pledge of Allegiance	03
3.	Quorum Call	03
4.	Call for Additional Agenda Items & Adoption of Agenda	04
5.	Consideration of Draft Minutes from Previous Meeting	04
6.	Report on Action Items	04
7.	Confirmation of Acts	04
8.	Opportunity for Public Comment	05
9.	Special Orders of the Day	05
10.	Committee Reports	
	A. Finance	05
	B. Application Review	06
	C. Reciprocity	06
	D. Violations	06
	E. Impairment	07
	F. Reinstatement	08
	G. Tripartite	09
	H. Regulation Revision	09
	I. Executive	12
11.	Staff Reports	
	A. General Counsel	16
	B. Executive Director	19
12.	New Agenda Items Added During Meeting	20
13.	Announcements	20
14.	Adjourn	20

The Louisiana Board of Pharmacy (the “Board”) convened a regular meeting on **Wednesday, August 20, 2025** at the Louisiana Board of Pharmacy located at 3388 Brentwood Drive in Baton Rouge, Louisiana 70809. The meeting was held pursuant to public notice, each member received notice, and public notice was properly posted.

**1. Call to Order**

Mr. Marty McKay, President, called the meeting to order at 9:03 a.m.

**2. Invocation & Pledge of Allegiance**

Dr. J. Robert Cloud delivered the invocation and Mr. Don L. Resweber led the group in the Pledge of Allegiance.

**3. Quorum Call**

Mr. McKay called upon Mr. Richard M. Indovina, Jr., Secretary, to call the roll of members to establish a quorum.

**Members Present:**

Dr. J. Robert Cloud, PharmD  
Mr. David A. Darce  
Ms. Jennifer E. Dupree  
Ms. Jacqueline L. Hall  
Mr. Richard M. Indovina, Jr.  
Mr. W. Charles Jones  
Mr. Marty R. McKay  
Ms. Chris B. Melancon  
Mr. J. Troy Menard  
Mr. Anthony G. Mercante  
Mr. Robert A. “Butch” Ray  
Mr. Don L. Resweber  
Mr. Richard A. “Andy” Soileau  
Dr. Raymond J. Strong, PharmD

**Members Absent:**

Dr. David G. Collins, PharmD  
Mr. Kevin LaGrange  
Mr. Richard Mannino

**Staff Present:**

Mr. M. Joseph Fontenot Jr., Executive Director  
Mr. Carlos M. Finalet, III, General Counsel  
Ms. Becky C. Parker, Compliance Officer  
Mr. Benjamin S. Whaley, Chief Compliance Officer  
Ms. Kelley L. Villeneuve, Office Manager

Guests:

Mr. Gerald Pannell  
Mr. Richard Oubre  
Mr. Lawrence LeDuff  
Mr. Jeff Gaudet – Walgreens  
Mr. Rob Geddes – CVS  
Mr. Gerard Johnson – CRW  
Mr. Dale Masten – Genoa Healthcare  
Mr. Malcolm J. Broussard – Hygeia Solutions  
Ms. Kim Dodd Boasso – PharmCare of LA  
Ms. Jessica Elliott – Louisiana Alliance of Retail Pharmacies (LARP)

Secretary Indovina certified 14 members were present, constituting a quorum for the conduct of official business.

**4. Call for Additional Agenda Items & Adoption of Agenda**

Mr. McKay asked if there were any additional agenda items to be added; none were requested. Without objection, the members adopted the posted agenda dated August 14, 2025. There were no objections to Mr. McKay's request for authority to re-order the agenda should the President determine it appropriate to do so.

**5. Consideration of Draft Minutes from Previous Meeting**

Mr. McKay reminded the members they had received the draft minutes from the regular Board meeting held on May 7, 2025. With no objections, he waived the reading of the draft minutes. With no requests for amendments or corrections, and with no objection, Mr. McKay declared the minutes were approved as presented.

**6. Report on Action Items**

Mr. McKay called upon Mr. Fontenot to present the report. Mr. Fontenot referred members to the report provided in the meeting materials and indicated his availability to address any questions. No questions or comments were offered.

**7. Confirmation of Acts**

Pursuant to Mr. McKay's declaration that the officers, members and committees, and executive director had attended to the business of the Board since their last meeting in accordance with policies and procedures previously approved by the Board, Ms. Hall moved:

***Resolved***, that the decisions made and the actions taken by the Board officers, members and committees, and executive director in the general conduct and transactions of Board business since May 7, 2025 are approved, adopted, and ratified by the entire Board.

With no discussion from Board members and no public comments, the motion was unanimously approved.

## **8. Opportunity for Public Comment**

Mr. McKay reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and for each agenda item upon which a vote is to be taken. He solicited general comments on non-agenda items from the guests present; none were offered.

### **\* Statement of Purpose**

Mr. McKay reminded the members of the purpose and mission of the Board of Pharmacy by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the members to keep their legislative mandate in mind as they considered all the matters before them.

## **9. Special Orders of the Day**

Mr. McKay presented Gold Pharmacist Certificates to the following pharmacists, sharing a synopsis of each recipient's professional service during the presentation:

- Lawrence D. LeDuff – PST.010650
- Richard J. Oubre – PST.010657
- Gerald P. Pannell – PST.010658
- Gerard M. Johnson – PST.010709
- Richard A. Soileau – PST.010719

The members and guests congratulated these pharmacists with generous applause.

## **10. Committee Reports**

### **A. Finance Committee**

Mr. Soileau introduced Mr. Russ Champagne and Ms. Penny Scruggins with Champagne & Company, LLC, the firm providing the Board's professional accounting services. Mr. Champagne and Ms. Scruggins then presented the Board's *Compiled Financial Statements for Fiscal Year 2024-2025*.

Mr. Soileau informed the members that the committee reviewed the report the previous day and voted to recommend acceptance of the report, subject to legislative audit. On behalf of the committee, Mr. Soileau moved:

***Resolved, to accept the Compiled Financial Statements for Fiscal Year 2024-2025 as the Board's final report, subject to legislative audit.***

With no discussion from Board members and no public comments, the motion was unanimously approved.

Mr. Soileau concluded his report by recognizing the other members of the committee: Dr. Collins, Mr. Jones, Ms. Melancon and Mr. Ray.

### **B. Application Review Committee**

Mr. McKay called upon Ms. Melancon for the committee report. Ms. Melancon reported that since the last Board meeting, no applications requiring committee review have been received, and therefore, the committee has not convened.

Ms. Melancon concluded her report by recognizing fellow committee members: Dr. Collins, Mr. Darce, Mr. Mannino and Mr. Ray.

### **C. Reciprocity Committee**

Mr. McKay called upon Mr. Fontenot, in the absence of Mr. Mannino, for the committee report. He reported that during Fiscal Year 2024-2025, 287 applicants were evaluated by staff and found to be eligible for licensure by reciprocity. None of them required an interview by the committee. In conformance with the policies and procedures previously approved by the Board, their applications were approved and their licenses were issued by the staff. A list of the pharmacists who were licensed by reciprocity during last fiscal year was included in the meeting material.

Mr. Fontenot concluded the report by recognizing the committee members: Mr. Darce, Mr. LaGrange, Mr. Mannino, Mr. Mercante, Mr. Ray, and Mr. Soileau.

### **D. Violations Committee**

Mr. McKay called upon Mr. Indovina for the committee report. Mr. Indovina reported the committee met on June 10-11, 2025 to consider several cases on their agenda. Following their interviews and subsequent deliberations, the committee developed recommendations for the Board's consideration. Mr. Indovina directed the members to copies of those proposals in their meeting materials and then proceeded to present the following cases:

**Daniel Pharmacy, LLC, dba Daniel Pharmacy (Brusly, LA) (PHY.008230):** Mr. Indovina moved to approve the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For permitting an individual with a lapsed credential to engage in the practice of pharmacy, the Board issued a letter of warning; and further, assessed a fine of \$1,000 plus administrative and investigative costs.

**Patrick Joseph LaBorde (PST.024203):** Mr. Indovina moved to approve the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For engaging in the practice of pharmacy with a lapsed credential, the Board issued a letter of warning; and further, assessed a fine of \$1,000 plus administrative costs.

**Dwayne Emile Hammer, Jr. (PST.022121):** Mr. Indovina moved to approve the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For falsifying documentation related to pharmacy staff compliance with sterile compounding competency requirements, the Board issued a letter of reprimand; and further, assessed a fine of \$2,500 plus administrative and investigative costs.

**Bocage Pharmacy Centre, Inc, dba Bocage Pharmacy Centre (Baton Rouge, LA) (PHY.006047):** Mr. Indovina moved to approve the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For improper closure of a pharmacy and improper transfer of controlled substance inventory, the Board permanently revoked the credential without opportunity for reinstatement.

**Marc Devereaux Gibbens (PST.014051):** Mr. Indovina moved to approve the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For his accountability as PIC of Bocage Pharmacy Centre (PHY.006047) regarding improper closure of the pharmacy and improper transfer of controlled substance inventory, the Board imposed restrictions upon him from having ownership of any Louisiana-permitted pharmacy and from holding the position of PIC; and further, assessed a fine of \$5,000 plus administrative and investigative costs.

**True Rx Management Services, Inc (PBM.000053):** Mr. Indovina moved to approve the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For providing services as a pharmacy benefit manager (PBM) in Louisiana prior to being credentialed, the Board assessed a fine of \$25,000 plus administrative and investigative costs.

**WellDyneRx, LLC (PBM.000045):** Mr. Indovina moved to approve the proposed voluntary consent agreement. Following discussion among Board members and with no public comments, the motion was unanimously approved. For providing services as a PBM in Louisiana prior to being credentialed, the Board assessed a fine of \$60,000 plus administrative and investigative costs.

**Script Care Ltd (PBM.000032):** Mr. Indovina moved to approve the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For providing services as a PBM in Louisiana prior to being credentialed, the Board assessed a fine of \$50,000 plus administrative and investigative costs.

Mr. Indovina concluded his report by announcing the next scheduled committee meeting on September 9, 2025, to consider 10 cases. He also recognized Dr. Cloud, Ms. Dupree, Ms. Hall, and Mr. Mercante for their service on the committee.

#### ***E. Impairment Committee***

Mr. McKay recognized Ms. Hall to deliver the committee report. Ms. Hall reported that the committee convened the previous day. After conducting interviews and engaging in subsequent deliberations, the committee developed recommendations for the Board's consideration. She then proceeded to present the following cases:

**Brooke Renee Gibson (PST.020955):** Ms. Hall moved to approve the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. The Board suspended her license for five years, beginning on August 20, 2025, and terminating on August 20, 2030, suspended the suspension, then placed her credential on probation for the period of the suspension, subject to certain conditions enumerated within the voluntary consent agreement.

**John Scott Soileau (PST.014858):** Ms. Hall moved to remove all probationary terms and conditions from the May 26, 2021 Board order. With no discussion from Board members and no public comments, the motion was unanimously approved. The Board granted his request, removing all probationary terms and conditions from the May 26, 2021 Board order, except for the permanent restriction on pharmacy ownership.

Ms. Hall reported that the committee reviewed and recommended the approval of David J. Daigle, MD, as an addition to the list of Board-Approved Addictionists. Ms. Hall then moved:

***Resolved, to approve the addition of David J. Daigle, MD, to the Roster of Approved Addictionists.***

With no discussion from Board members and no public comments, the motion was unanimously approved.

Ms. Hall concluded her report by recognizing fellow committee members: Dr. Collins, Mr. Darce, Mr. Menard, Mr. Resweber and Dr. Strong.

#### **F. Reinstatement Committee**

Mr. McKay recognized Dr. Strong for the committee report. Dr. Strong reported the committee convened the previous day. After conducting interviews and engaging in subsequent deliberations, the committee developed recommendations for the Board's consideration. He then proceeded to present the following cases:

**Christy Darlene Colvin (CPT.009658):** Dr. Strong moved to approve the request for reinstatement of the lapsed pharmacy technician certificate, contingent upon the completion of at least 250 hours of updated practical experience under the authority of a special work permit prior to August 20, 2027, in accordance with the terms of the Board order. With no discussion from Board members and no public comments, the motion was unanimously approved.

**Parkway Pharmacy South, LLC, dba Parkway Pharmacy South (Richwood, LA) (PHY.008353):** Dr. Strong moved to remove all probationary terms imposed by the Board Order issued on February 15, 2023, and restore the credential to an active and unrestricted status. With no discussion from Board members and no public comments, the motion was unanimously approved.



**Lateef Abioye Odeyemi (PST.022134):** Dr. Strong moved to remove all probationary terms imposed by the Board Order issued on February 15, 2023, and restore the credential to an active and unrestricted status. With no discussion from Board members and no public comments, the motion was unanimously approved.

Dr. Strong referred the members to the posted committee meeting agenda for a listing of all interim reinstatement actions by the committee chair and staff.

Dr. Strong concluded his report by recognizing fellow committee members: Ms. Dupree, Mr. Jones, Mr. LaGrange, Mr. Mannino, and Mr. Mercante.

#### **G. Tripartite Committee**

Mr. McKay recognized Mr. Resweber for the committee report. Mr. Resweber reported that the committee has not met since the last Board meeting and, therefore, had no report at this time.

Mr. Resweber concluded his report by recognizing fellow committee members: Ms. Dupree, Mr. Jones, Mr. LaGrange, Mr. Menard, and Dr. Strong.

At this point, Mr. McKay declared a recess. It was noted the members recessed at 9:53 a.m. and reconvened at 10:01 a.m.

#### **H. Regulation Revision Committee**

Mr. McKay called upon Dr. Cloud for the committee report. Dr. Cloud reported that the committee last convened on June 18, 2025, to review five regulatory proposals and to conduct a rule review pursuant to Governor Landry's Executive Order No. 25-038 and Act 192 of the 2024 Regular Session. As a result of that meeting, the committee developed several recommendations.

He directed members to the relevant items included in the meeting materials. For the benefit of the public, he advised that copies of proposals are accessible through the links provided on the meeting agenda and are also available on the Board's website.

Dr. Cloud then presented the following information:

- Regulatory Proposal 2025-A: Prescription Drug Delivery (Draft #3)  
On August 20, 2024, the Board published the final rule concerning Product Integrity, which addressed drug storage requirements. During the development of that rule, the committee also considered whether to include prescription drug delivery requirements. However, it was agreed to defer that topic and address it through a separate regulatory proposal, which is now presented for consideration.

This proposal focuses on delivery requirements as they relate to the statutory definition of "dispense" in state law. As defined: *"Dispense" or "dispensing" means the interpretation, evaluation, and implementation of a prescription*

drug order, including the preparation and delivery of a drug or device to a patient or patient's agent in a suitable container, appropriately labeled for subsequent administration to, or use by, the patient. "Dispense" necessarily includes a transfer of possession of the drug or device to the patient or the patient's agent.

It has been the Board's long-standing position, based on this definition, that simply releasing a prepared prescription to a third-party carrier, such as FedEx or UPS, does not complete the dispensing process. The pharmacy retains responsibility for the product's integrity until the patient actually takes possession.

When a pharmacy uses a common or contracted carrier, the chain of custody is broken upon release to that carrier. The pharmacy no longer has control over environmental conditions or physical possession, and therefore cannot ensure product integrity. As a result, returned products handled by third-party carriers cannot be reused.

In contrast, if a pharmacy uses its own pharmacy employee for delivery, it maintains custody and environmental control until the product reaches the patient, thus preserving product integrity and regulatory compliance.

The committee asked Mr. Finalet to research "possession or control" to better understand its scope. His findings indicated that in legal terms, "possession or control" means that a person has either physical custody of something (possession) or the power to exert influence or direct access to something, even if they don't physically hold it (control); essentially signifying that someone has the ability to use or dispose of an item, regardless of whether they are holding it directly.

Key points about "possession or control":

- *Broader than just physical possession:* This phrase goes beyond simply having something in your hand and can include situations where you have the authority to access or manage something, even if it's stored elsewhere.
- *Relevant in discovery:* In legal proceedings, "possession or control" is often used in discovery requests, where a party must produce documents or information that are within their "possession, custody, or control".
- *Can be complex in practice:* Determining whether someone has "possession or control" can be nuanced depending on the specific situation and may involve legal interpretation, especially when dealing with digital information.

The committee also learned that some contracted and common carriers provide delivery services designed to maintain product integrity, while allowing the contracting party to maintain control through formal agreements.

In response to this information, the committee developed the proposal. On behalf of the committee, Dr. Cloud moved:

***Resolved, to approve Regulatory Proposal 2025-A: Prescription Drug Delivery, Draft #3; and further, to authorize the Executive Director to promulgate the proposed rule changes; and further, to authorize the President to approve any necessary amendments that may arise during the promulgation process.***

With no discussion from Board members and no public comments, the motion was unanimously approved.

- Regulatory Proposal 2024-K: Centralized Prescription Dispensing (Draft #4)  
This proposal seeks to amend Section 1141 of the Board's rules governing centralized prescription dispensing. It clarifies requirements related to labeling, recordkeeping, the delivery of prescriptions between the remote dispenser and the on-site pharmacy, product returns, and the handling of controlled substances.

Following extensive review and multiple revisions, the committee finalized Draft #4 and voted to recommend its approval. On behalf of the committee, Dr. Cloud moved:

***Resolved, to approve Regulatory Proposal 2024-K: Centralized Prescription Dispensing, Draft #4; and further, to authorize the Executive Director to promulgate the proposed rule changes; and further, to authorize the President to approve any necessary amendments that may arise during the promulgation process.***

With no discussion from Board members and no public comments, the motion was unanimously approved.

- Regulatory Proposal 2025-D: Prescription Monitoring Program (PMP) Record Retention (Draft #1)  
Act 159 of the 2025 Regular Session expanded the Board's authority by adding "audit trail information" to the types of Prescription Monitoring Program (PMP) data for which the Board may establish standards for retention, archiving, and destruction through rulemaking. This proposal would amend Section 2914 of the Board's rules to include "audit trail information" within the scope of PMP record retention requirements.

Following its review of the proposal, the committee voted to recommend approval. On behalf of the committee, Dr. Cloud moved:

***Resolved***, to approve Regulatory Proposal 2025-D: Prescription Monitoring Program (PMP) Record Retention, Draft #1; and further, to authorize the Executive Director to promulgate the proposed rule changes; and further, to authorize the President to approve any necessary amendments that may arise during the promulgation process.

With no discussion from Board members and no public comments, the motion was unanimously approved.

- **Regulatory Proposal 2025-F: Controlled Dangerous Substances (Draft #2)**

This proposal would amend Chapter 27 of the Board's rules relating to controlled dangerous substances (CDS). Chapter 27, largely mirrors the Code of Federal Regulations (21 CFR Parts 1300–1399) but there are differences. Each time the federal regulations change, corresponding updates must be made to Chapter 27. This redundancy also places an unnecessary burden on CDS licensees, who must comply with both sets of regulations. This proposal seeks to streamline the regulatory framework by adopting the federal regulations by reference and consolidating any provisions that differ from the CFR into Section 2713. All remaining sections containing redundant requirements would be repealed.

Following its review of the proposal, the committee developed Draft #2 and voted to recommend approval. On behalf of the committee, Dr. Cloud moved:

***Resolved***, to approve Regulatory Proposal 2025-F: Controlled Dangerous Substances (CDS), Draft #2; and further, to authorize the Executive Director to promulgate the proposed rule changes; and further, to authorize the President to approve any necessary amendments that may arise during the promulgation process.

With no discussion from Board members and no public comments, the motion was unanimously approved.

Dr. Cloud concluded his report by acknowledging the contributions of fellow committee members: Mr. Darce, Ms. Hall, Mr. Indovina, Ms. Melancon, Mr. Menard, and Mr. Soileau.

***I. Executive Committee***

Mr. McKay reported that the committee met the previous day to consider the items on its posted agenda. He noted that Ms. Hall was prepared to present motions on behalf of the committee and reminded members that the related documents were included in the Board meeting materials.

- **Review & Consideration of Compliance Questionnaire for the Annual Legislative Audit**

Mr. McKay explained, as a state agency, the Board is subject to an annual financial audit for the preceding fiscal year. A required component of this audit

is the completion of the Louisiana *Compliance Questionnaire*. This document must be reviewed and formally adopted by the Board through a resolution in an open meeting. Following adoption, it must be signed by both the Board President and Secretary before submission to the Legislative Auditor.

Staff prepared the *Compliance Questionnaire* for the 2024–2025 fiscal year. The draft document was made available for member review in the Board library. The Executive Committee conducted a review of the document during its meeting yesterday. Ms. Hall then moved:

***Resolved, to approve the Louisiana Compliance Questionnaire for the Fiscal Year 2024-2025 Legislative Financial Audit.***

With no discussion from Board members and no public comments, the motion was unanimously approved.

- Review and Consideration of the Annual Report

Mr. McKay stated that the committee reviewed the report and voted to recommend approval and authorize its submission and filing. Ms. Hall then moved:

***Resolved, to approve the Annual Report for Fiscal Year 2024-2025, and to direct its filing with the Office of the Governor, the Health & Welfare Committees of the Senate and House of Representatives, the David Poynter Legislative Research Library, the Louisiana State Library, and its subsequent publication on the Board's website.***

With no discussion from Board members and no public comments, the motion was unanimously approved.

- Review of Comments from the Public Hearing held on June 26, 2025

Mr. McKay reported that pursuant to Louisiana R.S. 49:964(B), agencies engaged in rulemaking are required to conduct a public hearing at least once every six years to receive input from interested parties on any rule they believe to be contrary to law, outdated, unnecessary, overly complex, or burdensome.

The Board held its public hearing on June 26, 2025, to fulfill this requirement. In response to the public hearing notice, the Board received comments from three petitioners.

The statute further requires the Board to fully consider all comments and to respond to each submission, outlining the principal advantages and disadvantages of the proposed rule changes.

Following a review by the Board, Mr. McKay decided to refer these comments to the Regulation Revision Committee for further analysis and to develop recommendations for the Board's consideration.

- Proposed Repeal PPM.I.B.3.b – Open Meetings by Electronic Means – PBM Monitoring Advisory Council

Mr. McKay explained that Act 474, enacted during the 2025 Regular Legislative Session, revised the composition of the PBM Monitoring Advisory Council, reducing its membership from 25 to 13 members. As part of this restructuring, the Board of Pharmacy, the Medical Board, and several practitioner organizations were removed from the Council.

As a result of the Board's removal, the existing policy regarding open meetings by electronic means is no longer applicable. The committee therefore recommends its repeal. Ms. Hall then moved:

***Resolved, to repeal PPM.I.B.3.b – Open Meetings by Electronic Means – PBM Monitoring Advisory Council.***

With no discussion from Board members and no public comments, the motion was unanimously approved.

- Proposed Revision PPM.I.B.6 – Board Liaisons to Other Entities (Draft #1)

Mr. McKay stated that this policy outlines the boards, committees, task forces, and councils on which the Board of Pharmacy holds membership or representation. Upon review, staff identified the need to update the policy by removing references to the PBM Monitoring Advisory Council and the Employment & Medical Marijuana Task Force, as well as revising the language related to the Medicaid P&T Committee. Ms. Hall then moved:

***Resolved, to approve proposed revision PPM.I.B.6 ~ Board Liaisons to Other Entities, Draft #1.***

With no discussion from Board members and no public comments, the motion was unanimously approved.

- Proposed Revision PPM.I.C.1 – Executive Committee – Expense Report Guidelines – Travel Budget (Draft #2)

Mr. McKay explained that in 1998, the Board established a budget allowance of up to \$2,000 per member, per fiscal year, to support attendance at Board-approved conferences. Over the past 27 years, the cost of conference registration, lodging, and travel has increased substantially. After reviewing the policy, the committee determined that a \$1,000 increase is both reasonable and necessary to reflect current expenses.

Additionally, the committee identified areas of the policy that require clarification or revision, including the prohibition of alcohol reimbursement

and the delineation of committees involved in the travel budget approval process. Ms. Hall then moved:

***Resolved, to approve proposed revision PPM.I.C.1 – Executive Committee – Expense Report Guidelines – Travel Budget, Draft #2.***

Mr. McKay then elaborated on the current costs to attend beneficial conferences. With no discussion from Board members and no public comments, the motion was unanimously approved.

- Proposed Revision PPM.II.D.2.a – Record Retention Schedule, Item No. 308 – Criminal History Information (Draft #1)

Mr. McKay reported that staff identified a needed amendment to our current record retention schedule which addresses the retention period for criminal history information collected by the Board. Ms. Hall then moved:

***Resolved, to approve proposed revision PPM.II.D.2.a – Record Retention Schedule, Item No. 308 – Criminal History Information, Draft #1.***

Mr. McKay requested that Mr. Finalet further explain the need for this revision. Mr. Finalet explained the requirements for the Board to comply with federal laws regarding the disclosure of criminal background check information.

With no further discussion from Board members and no public comments, the motion was unanimously approved.

- Request for Rescission and Expungement of Board Action

Mr. McKay explained, Act 229 of the 2025 Regular Legislative Session allows for the rescission of Board actions and the expungement of related records when specific conditions are met.

On August 1, 2025, the effective date of the Act, the Board received a written request from a pharmacy permit holder seeking rescission of Board actions and expungement of records related to two Consent Orders.

The permit holder submitted documentation demonstrating that all requirements outlined in LA R.S. 37:1249.1 were satisfied. In accordance with Act 229, the Board is therefore required to issue an order rescinding the prior actions and expunging the adjudication records associated with those Consent Orders. Ms. Hall then moved:

***Resolved, to rescind the Consent Orders and expunge the related records pursuant to LA R.S. 37:1249.1.***

With no discussion from Board members and no public comments, the motion was unanimously approved.

- Consideration of Office of Public Health (OPH) Pharmacy Procedures  
Mr. McKay explained that in 1994, in accordance with Act 474 of the 1993 Louisiana Legislature (RS 37:933), the Board of Pharmacy approved an Office of Public Health (OPH) pharmacy protocol allowing nurse practitioners in OPH Clinics to distribute take-home doses to patients. This protocol has been in continuous use since then.

OPH Pharmacy now seeks to update the process for replenishing clinic drug inventories by incorporating electronic health record technology and is requesting the Board's approval. Ms. Hall then moved:

***Resolved, that the Board approve the updated Office of Public Health (OPH) pharmacy procedures, as developed by the OPH Director of Pharmacy, for the distribution of medication in accordance with LA R.S. 37:933.***

With no discussion from Board members and no public comments, the motion was unanimously approved.

- Exceptions Report  
Mr. McKay reported that, in accordance with Board policy, the Board President is authorized to review and respond to requests for exceptions to laws, rules, and policies between Board meetings. The policy also authorizes the Executive Director, with the concurrence of the Board President, to issue Special Work Permits and approve dual PIC privileges, with notice provided to the Board at its next meeting. The committee reviewed the current *Exceptions Report* available in the Board member reading room, which is now presented to the full Board as required. No action is required. There were no questions or comments from members.

Mr. McKay concluded his report by acknowledging the contributions of fellow committee members: Ms. Hall, Mr. Resweber, Dr. Cloud, and Mr. Indovina.

## **11. Staff Reports**

### **A. Report of General Counsel**

Mr. McKay recognized Mr. Finalet to present his report. Mr. Finalet first reported to the members that the Board is no longer a defendant in the lawsuit regarding Act 246 of the 2024 Legislature, a state law which included reclassifying mifepristone and misoprostol as controlled dangerous substances in Louisiana. The Board was represented by Ms. Celia Cangelosi.

Mr. Finalet then submitted the following proposed voluntary staff consent agreements for the Board's consideration:

**Amy Marisha Comeaux (CPT.016454):** Ms. Hall moved to accept the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For her failure to report



an adverse action as part of her pharmacy technician renewal application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Kayla Renee Champagne (CPT.013346):** Mr. Indovina moved to accept the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For an alleged diversion of controlled substances, the Board revoked her credential; and further, prohibited her from applying or reapplying to practice or assist in the practice of pharmacy.

**D'Tonya Dalinda Spottsville (CPT.014333):** Ms. Hall moved to accept the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For her failure to report an adverse action as part of her pharmacy technician renewal application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Madison Claire Cormier (CPT.016887):** Ms. Hall moved to accept the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For her failure to report an adverse action as part of her pharmacy technician renewal application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Tramaine Preston Smith (PST.023319):** Ms. Hall moved to accept the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For his failure to report a May 2021 board order issued by the Alabama State Board of Pharmacy as part of his 2022 Louisiana pharmacist license renewal application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$1,000 plus administrative costs.

**Tiara Von'Kitra Pembroke (CPT.015364):** Ms. Hall moved to accept the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For her failure to report an adverse action as part of her pharmacy technician renewal application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Destiny Shianne Snyder (CPT.017709):** Ms. Hall moved to accept the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For her failure to report an adverse action as part of her pharmacy technician renewal application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Shea Lynn Williams (CPT.016386):** Ms. Hall moved to accept the proposed

voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For her failure to report an adverse action as part of her pharmacy technician renewal application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Anastaisia Yvette Jordan (CPT.010046):** Ms. Hall moved to accept the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For her failure to report an adverse action as part of her pharmacy technician renewal application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Joshe' Shade' Brown (CPT.017634):** Ms. Hall moved to accept the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For her failure to report an adverse action as part of her pharmacy technician renewal application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Stephenique Moenicia Moore (CPT.017242):** Ms. Hall moved to accept the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For her failure to report an adverse action as part of her pharmacy technician renewal application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Chelsea Ann Robertson (CPT.011190):** Ms. Hall moved to accept the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For her failure to report an adverse action as part of her pharmacy technician renewal application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Princess Louella Hughes (CPT.014980):** Ms. Hall moved to accept the proposed voluntary consent agreement. With no discussion from Board members and no public comments, the motion was unanimously approved. For her failure to report an adverse action as part of her pharmacy technician renewal application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Meredith Kelly Fleck (CPT.007195):** Ms. Hall moved to accept the proposed voluntary consent agreement. After discussion from Board members and no public comments, the motion was unanimously approved. For her failure to report an adverse action as part of her pharmacy technician renewal application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

Mr. Finalet then indicated completion of his report.

**B. Report of the Executive Director**

Mr. McKay called upon Mr. Fontenot to present his report. Mr. Fontenot referred members to the quarterly report of the Louisiana Prescription Monitoring Program (PMP) included in the meeting materials. There were no questions or comments from the members.

Mr. Fontenot then directed the members to review requests from 18 pharmacies seeking a waiver from the duty to submit zero prescription transaction reports to the PMP. Ms. Melancon then moved:

***Resolved***, to authorize the issuance of full PMP reporting waivers to the following permits once they have executed the standard consent agreement for that purpose:

<b><u>Permit No.</u></b>	<b><u>Permit Name</u></b>
PHY.008991-NR	AMRx
PHY.004674-HOS	Bunkie General Hospital Pharmacy
PHY.008959-NR	ClearMedix Pharmacy
PHY.009005-HOS	Cornerstone Post Acute Care of Bossier
PHY.008975-NR	CSI Pharmacy
PHY.008993-NR	HealthDyne Pharmacy CO, LLC
PHY.008995-NR	HealthDyne Specialty Colorado, LLC
PHY.009025-NR	Kroger Pharmacy #011
PHY.008968-SAT	Ochsner Cancer Center of Acadiana
PHY.008992-HOS	ReCenter
PHY.009000-HOS	RISE Community Hospital
PHY.008980-NR	SelectRx KS, LLC
PHY.008940-NRN	SOFIE
PHY.009019-IR	Soleo Health Inc.
PHY.009008-NR	TrustedMedRx, LLC
PHY.008910-IR	Tulane University Health Sciences Pharmacy Lakeside
PHY.008982-NR	UK Specialty Pharmacy
PHY.008994-NR	West 35 <sup>th</sup> Apothecary, LLC

With no discussion from Board members and no public comments, the motion was unanimously approved.

**Annual Credentials Report**

Mr. Fontenot directed the members' attention to the *Census Report* for the Fiscal Year Ending 2025 and invited questions. Members engaged in brief discussion regarding the noted increases and decreases in specific credential categories.

Mr. Fontenot further presented the *New Credentials Report*, advising that a total of 7,588 credentials were issued by the Board during the fiscal year.

### **Annual Compliance Division Report**

Mr. Fontenot directed the members' attention to the *Complaint Investigation Completion Policy Monitor* report for the Fiscal Year Ending 2025 and provided an overview of the case load together with the associated turnaround times.

### **Bulletins**

Mr. Fontenot reported on the *Bulletins* issued on behalf of the Board. Copies were included in the meeting materials and are available on the Board's website. Mr. Fontenot then addressed questions from members.

Mr. Fontenot then indicated completion of his report.

## ***12. New Agenda Items Added During Meeting***

There were no new agenda items added during the meeting.

## ***13. Announcements***

Mr. McKay advised members of the upcoming meeting dates and reminded them that officer positions will be voted upon at the next meeting. Mr. Fontenot announced that a group photograph of the members will be taken on the morning of the next Board meeting as well. Members were also reminded of upcoming professional events and conferences. Mr. McKay confirmed that the newly adopted policy for travel will be in effect for the forthcoming meetings.

## ***14. Adjourn***

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board and without objection, Mr. McKay adjourned the meeting at 10:56 a.m.

*Minutes prepared by Joe Fontenot and then approved as presented during the subsequent meeting on November 19, 2025.*

---

Richard M. Indovina, Jr.  
Secretary